Table 4.
Factors Associated with the Development of Decreased Bone Mineral Density
| Parameter | Normal bone density (N=94) | Decreased bone density (N=58) | Odds ratio (95% CI) |
P value (univariate) |
P value (multivariate) |
|---|---|---|---|---|---|
| Menopausal status | 0.007* | ||||
| Postmenopausal (105) | 57 | 48 | 3.115 | 0.004* | |
| Premenopausal (47) | 37 | 10 | (1.404-6.914) | ||
| Adjuvant hormonal treatment | 0.009* | ||||
| Received (94) | 50 | 44 | 2.765 | 0.005* | |
| Not received (58) | 44 | 14 | (1.339-5.711) | ||
| Chemotherapy | |||||
| Taxane containing (105) | 64 | 41 | 1.13 | 0.74 | - |
| Without taxane (47) | 30 | 17 | (0.554-2.305) | ||
| Hormonal treatment | - | ||||
| Letrezole (49) | 24 | 25 | 1.425 | 0.392 | |
| Tamoxifen (45) | 26 | 19 | (0.631-3.21) |
* P < 0.05 was considered statistical significant; ++, There was significant association of decreased BMD and adjuvant hormonal treatment. Postmenopausal status was also significantly associated with the loss of bone mineral density. There was no significant difference in terms of BMD between Tamoxifen and Letrozole group.